Overview

Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function

Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This study is being done to assess the effects of S. boulardii CNCM I-745 compared to placebo on impaired intestinal permeability, which is the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall into the rest of the body.
Phase:
Early Phase 1
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Indomethacin